Adults living with both type 2 diabetes and attention-deficit/hyperactivity disorder face more than twice the risk of dying after their diabetes diagnosis compared with diabetes patients without ADHD, according to one of the largest multinational cohort studies ever assembled to examine this overlooked clinical intersection. The research, published in BMC Medicine, pooled population-based health data from seven countries—Australia, Denmark, the Netherlands, Norway, Sweden, the United Kingdom, and the United States—to track nearly two million adults with type 2 diabetes over a decade. The findings carry immediate implications for how clinicians manage a growing population of patients in whom a neurodevelopmental psychiatric condition and a chronic metabolic disease collide.
The scale of the investigation is what sets it apart. The research team, led by Zihan Dong of Karolinska Institutet in Sweden together with an international consortium spanning more than thirty institutions, identified 1,929,027 adults who received a first recorded diagnosis of type 2 diabetes between 2010 and 2020. Of these, roughly 47 percent were male. Because the study drew on national health registries, insurance claims databases, and prescription records rather than self-report, the researchers could capture ADHD diagnoses and medication dispensations with a degree of completeness that smaller single-country studies cannot match. Each national dataset was analysed under a standardized analytical protocol before the results were combined, a design choice that minimizes the methodological heterogeneity that has plagued earlier cross-study comparisons.
The headline result is stark: adults with type 2 diabetes and co-occurring ADHD had a hazard ratio of 2.42 for all-cause mortality after their diabetes diagnosis, with a 95 percent confidence interval of 1.72 to 3.41. In practical terms, even after accounting for the uncertainty inherent in observational data, the death rate among these patients was more than double that of their diabetes-only counterparts. Crucially, the association held after the researchers adjusted for sex, age, calendar year at diabetes diagnosis, psychiatric history, use of other psychotropic medications, and use of cardiometabolic drugs—the standard arsenal of confounders that critics of pharmacoepidemiology studies typically raise. The consistency of the signal across seven healthcare systems with different diagnostic cultures, treatment guidelines, and record-keeping infrastructures strengthens the case that the finding reflects a genuine clinical phenomenon rather than an artifact of any single country’s data.
Perhaps more surprising is what the study did not find. ADHD was not consistently associated with major adverse cardiac events—a composite outcome encompassing acute myocardial infarction, stroke, and cardiovascular disease-related death. The pooled hazard ratio for MACE was 1.04, with a confidence interval of 0.81 to 1.35, meaning the data cannot distinguish the true effect from no effect at all. This dissociation between mortality and cardiac events is scientifically intriguing. It suggests that the excess deaths among diabetes patients with ADHD may not be driven primarily by the classical cardiovascular pathway that dominates outcomes research in type 2 diabetes. Alternative explanations could include non-cardiac causes of death, difficulties with diabetes self-management, higher rates of psychiatric comorbidity, medication non-adherence, or lifestyle factors that are harder to capture in registry data. The authors note that the mortality signal was robust while the cardiac one was not, a pattern that warrants deeper investigation into the specific causes of death in this population.
The study also examined a second, clinically urgent question: among adults who have both type 2 diabetes and ADHD, does taking ADHD medication change cardiovascular risk? Here the answer was conditional and age-dependent. Overall, ADHD medication use was not associated with elevated MACE risk across the full cohort. But when the researchers stratified by age at diabetes onset, a clear signal emerged: among patients diagnosed with type 2 diabetes before age 45—so-called early-onset type 2 diabetes—ADHD medication use was associated with a hazard ratio of 1.58 for major adverse cardiac events, with a confidence interval of 1.18 to 2.10. That interval excludes the null value, indicating a statistically reliable elevation in risk within this younger subgroup.
The age stratification matters because early-onset type 2 diabetes is itself an aggressive disease. Patients diagnosed in early adulthood accumulate longer lifetime exposure to hyperglycemia and typically face higher cumulative risks of retinopathy, nephropathy, and cardiovascular complications than those diagnosed later in life. Layering stimulant and non-stimulant ADHD medications onto an already vulnerable metabolic profile may compound that risk. Stimulant medications such as methylphenidate and amphetamine derivatives act on the sympathetic nervous system, raising heart rate and blood pressure—effects that are generally well tolerated in healthy adults but potentially consequential in patients with insulin resistance, dyslipidemia, and emerging vascular disease. The study’s time-varying exposure design, which allowed medication status to change over the follow-up period rather than being fixed at baseline, lends additional credibility to this subgroup finding.
Methodologically, the researchers employed cause-specific Cox proportional hazards models, the workhorse of survival analysis, to estimate hazard ratios with 95 percent confidence intervals for each country separately. These country-specific estimates were then pooled using random-effects meta-analysis, a technique that assumes the true effect may vary across populations and quantifies that variability rather than pretending it does not exist. Treating both ADHD status and medication use as time-varying exposures was a deliberate safeguard against immortal time bias, a subtle distortion that arises when researchers classify patients by a status they could only achieve after surviving a certain period. The adherence to the STROBE reporting guidelines for observational epidemiology further signals the team’s attention to transparency and reproducibility.
The study was supported by the European Union Horizon 2020 Research and Innovation Programme, along with national funders including the Australian National Health and Medical Research Council, and the funders had no role in the design, analysis, or publication decisions. The authors declared a range of competing interests typical of a large psychiatric-pharmacoepidemiology collaboration, including speaker fees and research funding from pharmaceutical companies for several senior investigators, all reported as outside the submitted work. The article is published open access under a Creative Commons Attribution license, and the team has shared supplementary materials detailing the country-specific analyses.
For clinicians, the message is twofold. First, a diagnosis of ADHD in an adult with type 2 diabetes should prompt intensified monitoring and integrated somatic-psychiatric care, because the co-occurrence marks a population at substantially elevated risk of dying. Adults with ADHD are, on average, diagnosed with type 2 diabetes at younger ages and may experience greater difficulty adhering to complex medication regimens, dietary recommendations, and glucose monitoring routines—mechanisms the study’s authors flag as plausible contributors to the mortality gap. Second, the decision to prescribe ADHD medication to a patient with early-onset type 2 diabetes deserves careful individualized consideration, weighing the demonstrated benefits of treatment on function and safety against a possible cardiovascular signal in this vulnerable group. The researchers emphasize that their findings suggest a potential need for integrated care models and careful medication stewardship, particularly for younger-onset diabetes, rather than any blanket restriction on ADHD treatment.
The broader significance of the work lies in its demonstration that psychiatric comorbidity is not a peripheral concern in metabolic disease. As ADHD diagnoses in adults continue to rise and as type 2 diabetes increasingly affects younger populations, the overlap between the two conditions will grow. Studies of this scale, harnessing the combined statistical power of seven national data systems, provide the evidentiary foundation that single-country analyses cannot. What remains to be established is the mechanism: whether the doubled mortality reflects biological interactions, behavioral pathways, healthcare access disparities, or some combination of all three. Answering that question will determine whether the intervention that matters most is cardiological, psychiatric, or structural—and for now, the study’s authors argue, the safest bet is closer collaboration between the specialists who treat the brain and those who treat the blood sugar.
Subject of Research: The association of ADHD and ADHD medication use with major adverse cardiac events and mortality in adults with type 2 diabetes
Article Title: Major adverse cardiac events and mortality associated with ADHD and its treatment in adults with type 2 diabetes: a multi-national cohort study
Article References: Dong, Z., Zhou, Y., Yao, H., Liu, S., Astrup, A., Engeland, A., Gao, L., Gillies, M. B., Lunde, A., Zhang-James, Y., Araki, M., Brikell, I., Butwicka, A., Dalsgaard, S., D’Onofrio, B. M., Faraone, S. V., Gudbjornsdottir, S., Haavik, J., Kuja-Halkola, R., … Du Rietz, E. (2026). Major adverse cardiac events and mortality associated with ADHD and its treatment in adults with type 2 diabetes: a multi-national cohort study. BMC Medicine, 24(1), Article 527. https://doi.org/10.1186/s12916-026-05246-4
Image Credits: AI Generated
DOI: 10.1186/s12916-026-05246-4
Keywords: ADHD, type 2 diabetes, major adverse cardiac events, mortality, ADHD medication, cardiovascular risk, cohort study, pharmacoepidemiology, early-onset diabetes, multinational study, psychiatric comorbidity, BMC Medicine
Cite Scienmag News
APA MLA Chicago
Ophelia Keating. (October 3, 2026). ADHD Doubles Death Risk in Adults with Type 2 Diabetes, Landmark Seven-Nation Study Finds. Scienmag. https://scienmag.com/adhd-doubles-death-risk-in-adults-with-type-2-diabetes-landmark-seven-nation-study-finds/
Ophelia Keating. “ADHD Doubles Death Risk in Adults with Type 2 Diabetes, Landmark Seven-Nation Study Finds.” Scienmag, 3 October 2026, https://scienmag.com/adhd-doubles-death-risk-in-adults-with-type-2-diabetes-landmark-seven-nation-study-finds/. Accessed 3 October 2026.
Ophelia Keating. “ADHD Doubles Death Risk in Adults with Type 2 Diabetes, Landmark Seven-Nation Study Finds.” Scienmag. October 3, 2026. https://scienmag.com/adhd-doubles-death-risk-in-adults-with-type-2-diabetes-landmark-seven-nation-study-finds/
Copy citation Download RIS
Tags: ADHDADHD and type 2 diabetes comorbidityADHD medicationBMC Medicinecardiovascular riskclinical management of ADHD and diabetes comorbidityCohort studycross-country analysis ofearly onset diabetesglobal research on ADHD and metabolic diseaseimpact of neurodevelopmental disorders on chronic disease outcomesimplications of ADHD diagnosis for diabetes patient careincreased mortality risk in adults with ADHD and diabeteslarge-scale population health data on ADHD and diabeteslong-term health risks of ADHD in adults with diabetesmajor adverse cardiac eventsmortalitymultinational cohort study on ADHD and diabetesmultinational studypharmacoepidemiologypsychiatric comorbidityrole of psychiatric conditions in diabetes mortalityType 2 diabetes
